TITLE OF STUDY |
PHASE
|
INDICATION |
STATUS |
For definitions, visit Glossary |
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection |
II |
Asthma |
|
A multicenter, randomized, double-mask, placebo-controlled, parallel study to investigate the efficacy and safety of 20mg Tasimelteon versus placebo on totally blind subjects with N24HSWD followed by an ole phase |
III |
Sleep Disorder |
|
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF 2 DOSES OF ACLIDINIUM BROMIDE COMPARED WITH PLACEBO FOR 12 WEEKS IN PATIENTS WITH MODERATE TO SEVERE, STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE FOLLOWED BY A 40-WEEK EVALUATION OF THE 2 ACLIDINIUM BROMIDE DOSES |
II |
COPD |
Ongoing / Closed to Enrollment
|
A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler ® (500/400 µg) and mometasone furoate Twisthaler ® (400 µg) in adolescent and adult patients with persistent asthma |
II |
Asthma |
Ongoing / Closed to Enrollment
|
A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat ® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler ® |
IIIb |
COPD |
Ongoing / Closed to Enrollment
|
An Epidemiologic Study Of Xolair® (Omalizumab): Evaluating Clinical Effectiveness And Long-Term Safety In Patients With Moderate To Severe Asthma (EXCELS) |
Observational Survey |
Asthma |
Ongoing / Closed to Enrollment
|
Effect of Roflumilast on Exacerbation Rate in Patients with COPD. A 52-week, double-blind study with 500 mcg Roflumilast once daily versus placebo |
III |
COPD |
Ongoing / Closed to Enrollment
|
Closed Studies
Visit Closed Studies
|
